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Abstract
Cerebrospinal fluid (CSF) potentially carries an archive of peptides and small proteins relevant to
pathological processes in the central nervous system (CNS) and surrounding brain tissue.
Proteomics is especially well suited for the discovery of biomarkers of diagnostic potential in CSF
for early diagnosis and discrimination of several neurodegenerative diseases. ProteinChip surface-
enhanced laser-desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is one
such approach which offers a unique platform for high throughput profiling of peptides and small
proteins in CSF. In this study, we evaluated methodologies for the retention of CSF proteins < 20
kDa in size, and identify a strategy for screening small proteins and peptides in CSF. ProteinChip
array types, along with sample and binding buffer conditions, and matrices were investigated. By
coupling the processing of arrays to a liquid handler reproducible and reliable profiles, with mean
peak coefficients of variation < 20%, were achieved for intra- and inter-assays under selected
conditions. Based on peak m/z we found a high degree of overlap between the tested array surfaces.
The combination of CM10 and IMAC30 arrays was sufficient to represent between 80–90% of all
assigned peaks when using either sinapinic acid or α-Cyano-4-hydroxycinnamic acid as the energy
absorbing matrices. Moreover, arrays processed with SPA consistently showed better peak
resolution and higher peak number across all surfaces within the measured mass range. We intend
to use CM10 and IMAC30 arrays prepared in sinapinic acid as a fast and cost-effective approach to
drive decisions on sample selection prior to more in-depth discovery of diagnostic biomarkers in
CSF using alternative but complementary proteomic strategies.
Background
Human cerebrospinal fluid (CSF) is largely produced by
the highly vascular choroid plexus [1]. CSF continuously
circulates through cavities in the brain and spinal chord
and in the subarachnoid space, and contains peptides and
proteins that play critical roles in many physiological
processes [2]. Its proximity to the brain and the little risk
involved with procuring CSF samples from individuals
makes it an appropriate source of protein biomarkers for
neurodegenerative disease. CSF is in direct contact with
the extracellular space of the brain, and so contains some
proteins and other products of neural cell origin. As such,
any variation in protein composition or abundance rela-
tive to normal CSF may potentially reflect pathological
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processes in the surrounding brain tissue and other parts
of the central nervous system (CNS) [1,3-6]. Monitoring a
combination of biomarkers in CSF exhibiting high sensi-
tivity and specificity offers the potential for aiding early
stage diagnosis, when correct diagnosis is often difficult,
and when therapeutic compounds have the greatest
potential for being effective. Biomarkers could also be
used as quantitative indices of disease progression and
response to therapeutics, and for discriminating early or
incipient Alzheimer's disease (AD) from age-associated
memory loss impairment, depression, and some second-
ary dementias.
Similar to plasma, the predominant proteins in CSF are
isoforms of serum albumin, transferin and immunoglob-
ulins, which represent more than 70% of the total protein
amount. Furthermore, an unwanted high dynamic range
of protein abundance is found in CSF, making the detec-
tion of lower abundance proteins extremely challenging
with the current analytical methods. An additional chal-
lenge with analyzing CSF is protein concentration. On
average CSF contains 100 fold less protein than plasma,
therefore, necessitating the need for larger sample
amounts relative to plasma. A variety of proteomic
approaches have recently been used to characterize the
peptide and protein composition in CSF. Most of these
proteomic technology platforms are centered around the
implementation of mass spectrometric techniques in con-
junction with several other analytical techniques such as
gel electrophoresis, isoelectric focusing, and liquid chro-
matography (LC) [3,7-11]. While these approaches pro-
vide a large amount of data and can identify hundreds of
proteins, they are generally very time consuming and
hence restrictive in the number of comparative samples
that can be analyzed.
Surface-based enrichment approaches in combination
with MS is one such approach which offers a unique plat-
form for high throughput CSF protein profiling. Protein-
Chip surface enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF-MS) technology
(Ciphergen Biosystems Inc., Fremont, CA) was developed
to facilitate the high-throughput analysis of proteins in
complex biological samples such as body fluids [12-17].
This technology uses chip-based protein sample arrays
with different chromatographic surfaces designed to cap-
ture and retain subsets of proteins based on specific pro-
tein characteristics such as affinity, charge,
hydrophobicity, and metal-binding capabilities. After a
series of binding and washing steps of the chromato-
graphic surfaces, matrix is added to the spots and the sam-
ples are analyzed by laser desorption/ionization-TOF-MS
generating mass/charge profiles of the applied sample
[18]. Proteomic expression patterns derived from mass
spectrometry have been put forward as potential biomar-
kers of clinical relevance [19-21]. Such spectral profiles
can be compared to uncover patterns of differential abun-
dance and aid in the identification of diagnostic patterns
of disease and toxicity [13,15,22-25]. Moreover, surface-
based enrichment approaches have the potential to cap-
ture and enrich for low abundant, low molecular weight
species [12,17,22,26,27]. The low molecular weight
region of CSF comprising of peptides and fragments of
proteins remains relatively unexplored and represents a
potential treasure trove of histopathological information.
Although the ProteinChip SELDI-TOF approach is a
straightforward, robust platform for high throughput pro-
tein profiling, much has been discussed concerning its
poor representation of the proteome, particularly for pro-
teins above 20 kDa in mass. In this paper, however, we
take advantage of the technologies potential for screening
peptides and small proteins between the 2–20 kDa mass
window range, and its requirement of only small sample
volumes for analysis. As with any technology, experimen-
tal procedures must be optimized and reproducible to
ensure consistent data output. Therefore, the aim of this
paper was to improve on existing methodologies to iden-
tify effective conditions of retention for profiling proteins
in the low molecular weight region of the CSF proteome.
Results
Assessment of ProteinChip array types, buffer conditions 
and matrix for profiling CSF
Four ProteinChips (CM10, Q10, H50 and IMAC30) were
used for the detection of proteins present in CSF between
the m/z range of 2.5–20 kDa. In order to identify effective
conditions of protein retention, pooled human CSF sam-
ples were prepared under native, denatured, and dena-
tured/reduced conditions, and analyzed on ProteinChip
arrays processed using different buffer conditions and
matrices. For each condition of retention the samples
were processed in triplicate. The selection criteria used to
determine the choice of conditions for profiling CSF was
dependent on both the number and quality of resolved
peaks within the mass spectra. Tables 1 and 2 summarize
the number of peaks automatically detected between the
m/z range of 2.5–20 kDa across all tested conditions using
either SPA or CHCA as the energy absorbing matrices.
Peaks were required to have a signal to noise ratio of 3 or
greater in order to be considered. The representative pro-
files obtained from the tested conditions on arrays proc-
essed with SPA and CHCA are shown in figures 1 and 2,
for the respective matrices. Based on total peak count,
denatured samples consistently demonstrated a higher
number of resolved peaks when compared with samples
prepared under native or denatured/reduced conditions.
This was the case across all four ProteinChip arrays proc-
essed with either SPA or CHCA. When comparing peak
count between CM10 and Q10 arrays, slightly better pro-Proteome Science 2006, 4:7 http://www.proteomesci.com/content/4/1/7
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Representative SELDI-TOF MS spectra of pooled CSF sample obtained from all tested conditions using SPA as matrix Figure 1
Representative SELDI-TOF MS spectra of pooled CSF sample obtained from all tested conditions using SPA 
as matrix. CSF was processed on CM10, Q10, H50 and IMAC30 ProteinChip arrays prepared under the following conditions: 
CM10 a: Native – 100 mM ammonium acetate, pH 4.0 b: Native – 100 mM ammonium acetate/0.1% Triton X-100, pH 4.0 c: 
Denatured – 100 mM ammonium acetate, pH 4.0 d: Denatured – 100 mM ammonium acetate/0.1% Triton X-100, pH 4.0 e: 
Denatured/reduced – 100 mM ammonium acetate, pH 4.0 f: Denatured/reduced – 100 mM ammonium acetate/0.1% Triton X-
100, pH 4.0 Q10 a: Native – 100 mM Tris-HCl, pH 9.0 b: Native – 100 mM Tris-HCl/0.1% Triton X-100, pH 9.0 c: Denatured 
– 100 mM Tris-HCl, pH 9.0 d: Denatured – 100 mM Tris-HCl/0.1% Triton X-100, pH 9.0 e: Denatured/reduced – 100 mM 
Tris-HCl, pH 9.0 f: Denatured/reduced – 100 mM Tris-HCl/0.1% Triton X-100, pH 9.0 H50 a: Native – 10% AcN/0.1% TFA b: 
Native – PBS c: Denatured – 10% AcN/0.1% TFA d: Denatured – PBS e: Denatured/reduced – 10% AcN/0.1% TFA f: Dena-
tured/reduced – PBS IMAC30 a: Native – 100 mM Cu sulfate,100 mM Na phosphate/0.5 M NaCl, pH 7.0 b: Native – 100 mM 
Ni sulfate, 100 mM Na phosphate/0.5 M NaCl, pH 7.0 c: Denatured – 100 mM Cu sulfate, 100 mM Na phosphate/0.5 M NaCl, 
pH 7.0 d: Denatured – 100 mM Ni sulfate, 100 mM Na phosphate/0.5 M NaCl, pH 7.0 e: Denatured/reduced – 100 mM Cu sul-
fate, 100 mM Na phosphate/0.5 M NaCl, pH 7.0 f: Denatured/reduced – 100 mM Ni sulfate, 100 mM Na phosphate/0.5 M 
NaCl, pH 7.0
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Representative SELDI-TOF MS spectra of pooled CSF sample obtained from all tested conditions using CHCA as matrix Figure 2
Representative SELDI-TOF MS spectra of pooled CSF sample obtained from all tested conditions using CHCA 
as matrix. CSF was processed on CM10, Q10, H50 and IMAC30 ProteinChip arrays prepared under the same conditions as 
described in figure 1, but with CHCA as the energy absorbing matrix.
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files were obtained with both array types processed in the
absence of Triton X-100. In the case of IMAC30, surface
activation with copper provided the higher peak number
when compared to activation with nickel, whereas with
H50, higher peak numbers were obtained with 10% AcN/
0.1% TFA as binding buffer compared to PBS. Typically
for the analysis of proteins and peptides by MS, SPA is the
matrix of choice for large proteins, whereas CHCA is the
preferred matrix for peptides (< 4 kDa). Not surprising,
arrays processed with SPA consistently showed better peak
resolution and higher peak number across all surfaces
within the measured mass range of 2.5 to 20 kDa (tables
1 and 2).
Assessment of peak overlaps between ProteinChip array 
types
Peak profiles for CSF samples prepared in denaturing
buffer were compared across all four ProteinChip array
types to asses the extent of peak overlap between the dif-
ferent array types. The assessment of peak overlaps would
be used to determine the optimal combination of array
types, in terms of the number and resolution of peaks, to
be adopted for a CSF profiling strategy. Figure 3 shows
representative spectra of proteins retained on the four
array types prepared with SPA. When assigning peak clus-
ters across the different array types, peaks on different sur-
faces were assumed to be the same protein if their
respective m/z were within 0.3%. Nevertheless, it must be
mentioned that without assigned peak identities one can
never be confident that a peak of similar mass, observed
between the different array types, represents the same pro-
tein. A Venn diagram representing peak counts, deter-
mined as unique or common across the array types, is
shown in figure 4. A significant proportion of all detected
peaks were found to be common to two or more array
types. Approximately, 8 and 12 peaks were common to all
array types processed with SPA and CHCA, respectively,
out of which 6 peaks were common to all array types proc-
essed with both matrices (m/z  8740, 11956, 12055,
13996, 14122 and 14164). Overall, approximately 75 and
56 unique peaks (defined as only present on one surface)
were detected across all four arrays types prepared with
SPA and CHCA, respectively. The highest number of
unique peaks was observed on CM10 and IMAC30 arrays.
Table 1: Comparison of peak count between all tested conditions using SPA as matrix.
Native 9 M urea, 2% CHAPS 9 M urea, 2% CHAPS, 10 mM DTT
Peak count Average Peak count Average Peak count Average
CM10 w/o Triton X-100 103 103 121 117 102 100
104 112 90
101 119 99
Triton X-100 100 102 105 104 95 98
104 105 102
101 102 90
Q10 w/o Triton X-100 101 102 109 109 103 100
103 108 97
102 110 100
Triton X-100 89 90 105 106 104 104
90 105 104
91 108 103
H50 10% AcN, 01% TFA 104 101 103 105 98 102
99 103 109
100 109 101
P B S 7 67 97 47 27 77 6
82 74 74
78 70 77
IMAC30 Copper 102 99 100 113 97 103
95 110 106
97 131 106
Nickel 107 105 88 92 84 81
102 90 70
103 100 90
Peaks with a signal-to-noise of 3 or greater were assigned between the m/z range of 2.5–20 kDa. 5 µL of pooled CSF prepared under native, 
denaturing, and denaturing/reducing buffer was applied in triplicate to each condition tested on CM10, Q10, H50, and IMAC30 arrays.Proteome Science 2006, 4:7 http://www.proteomesci.com/content/4/1/7
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Moreover, the combination of CM10 and IMAC30 cov-
ered 89% and 79% of all detected peaks on SPA and
CHCA, respectively.
Assessment of spectral reproducibility
For comparative studies, reliable and reproducible protein
profiles must be obtained to ensure that the variation in
spectra reflects biological differences in protein concentra-
tion rather than systematic variability. As such, accurate
mass peak heights are necessary, and the technical varia-
tion of the profiles must be known. In order to increase
the reliability of the approach we adapted the entire
processing of arrays to a robotics system for consistency.
Intra-chip reproducibility was assessed using 6 technical
replicates of a pooled CSF sample spotted in equal vol-
umes (5µL) on four individual CM10 chips. A total of 30
randomly selected peaks with a signal-to-noise ratio >3,
and common to all spectra, were randomly selected and
compared with regards to their normalized peak intensi-
ties by calculating the CV within each chip. The mean CV
for intra-chip variability was 17%, ranging from 7–34%
across individual peaks. To evaluate the inter-chip varia-
bility, pooled CSF sample was randomly placed on a sin-
gle spot across each of twelve different CM10 chips on one
bioprocessor plate. This was repeated using a second bio-
processor plate processed the following day. A total of 37
peaks with a signal-to-noise ratio >3, and common to all
spectra, were randomly selected and compared with
regards to their normalized peak intensities by calculating
the CV within each bioprocessor. Mean peak CVs of 19%
(ranging from 6–29%) and 23% (ranging from 7–47%)
for normalized intensity were calculated for each bioproc-
essor. The spectra profiles for the inter-chip assay are
shown in figure 5. Overall, the CVs obtained for both
inter- and intra-chip indicate that the processing of pro-
tein chips across a bioprocessor using a robotic system is
reliable and reproducible.
In addition we evaluated the variability across three bio-
processor plates processed 4 and 24 hours apart. Pooled
Table 2: Comparison of peak count between all tested conditions using CHCA as matrix.
Native 9 M urea, 2% CHAPS 9 M urea, 2% CHAPS, 10 mM DTT
Peak count Average Peak count Average Peak count Average
CM10 w/o Triton X-
100
66 68 98 90 76 79
70 86 85
69 86 78
T r i t o n  X - 1 0 0 7 57 67 77 76 86 7
76 84 68
75 72 66
Q10 w/o Triton X-
100
86 86 91 87 82 75
86 89 74
86 82 70
T r i t o n  X - 1 0 0 7 77 57 38 17 57 1
73 89 70
74 81 70
H50 10% AcN, 01% 
TFA
71 71 85 81 73 73
72 80 73
71 80 73
P B S 6 06 26 36 35 95 8
64 63 61
62 65 55
IMAC30 Copper 93 89 99 104 77 82
85 109 81
88 106 89
Nickel 90 89 87 87 74 81
88 85 85
89 91 84
Peaks with a signal-to-noise of 3 or greater were assigned between the m/z range of 2.5–20 kDa. 5 µL of pooled CSF prepared under native, 
denaturing, and denaturing/reducing buffer was applied in triplicate to each condition tested on CM10, Q10, H50, and IMAC30 arrays.Proteome Science 2006, 4:7 http://www.proteomesci.com/content/4/1/7
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Representative SELDI-TOF MS spectra of CSF in denaturing buffer on CM10, Q10, H50 and IMAC30 arrays Figure 3
Representative SELDI-TOF MS spectra of CSF in denaturing buffer on CM10, Q10, H50 and IMAC30 arrays. a) 
CSF was diluted 1:1 in denaturing buffer 9.5 M urea, 2% CHAPS, 50 mM Tris-HCl, pH 9.0. Denatured CSF samples were 
diluted 1:4 in appropriate binding buffer and processed on: CM10 with 100 mM ammonium acetate pH 4.0; Q10 with 100 mM 
Tris-HCl pH 9.0; H50 with 10% AcN, 01% TFA; and IMAC30 with 100 mM Na phosphate, 0.5 M NaCl pH 7.0 and 100 mM Cu 
sulphate activation. ProteinChip arrays were prepared with SPA. b) Enlargement of the shaded spectra region showing peaks 
between m/z range of 4–11 kDa.
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CSF sample was randomly placed on a single spot across
each of twelve different CM10 chips on one bioprocessor
plate. The same was repeated for the other plates 4 and 24
h later. Figure 6 shows the principle component analysis
results for data points representing spectra of each sample
with color denoting the bioprocessor plate. The clustering
of points to their respective plates indicates the presence
of a discernable systematic variability across plates, with
the largest separation between clusters seen for the plate
processed at 24 h. This variability is very important in the
context of large studies in which a large number of bio-
processor plates would be needed. Intelligent randomiza-
tion procedures using technical replicates would need to
be adopted in order to minimize any systematic bias
introduced by plates and time of process.
Discussion
Surface-based enrichment approaches in combination
with MS, such as ProteinChip SELDI-TOF approach, have
been developed to facilitate the high-throughput analysis
of peptides and proteins in complex biological samples
such as body fluids. ProteinChip SELDI-TOF technology
allows for facile sample analysis since very small sample
volumes can be directly applied to the ProteinChip array
surfaces, and the process can be easily automated for high-
throughput analysis. In the present study, we applied the
ProteinChip SELDI-TOF approach coupled with an auto-
mated robotic sample preparation workstation as a strat-
egy for potentially screening large numbers of CSF
samples from clinical studies. In particular, we take
advantage of the technologies high-throughput potential
for screening proteins between the 2.5–20 kDa mass win-
dow range.
To date, few examples exist in the literature describing the
application of ProteinChip SELDI-TOF approach for ana-
lyzing CSF [28-33]. and none describe a comparative eval-
uation of CSF profiles across different conditions and
arrays. To our knowledge this paper is the first to describe
a comparative investigation of experimental procedures
for identifying effective and consistent conditions for
retention of CSF proteins on different ProteinChip array
types between the 2.5–20 kDa mass range. ProteinChip
array types, along with sample and binding buffer condi-
tions, and matrices were evaluated based on the number
of resolved peaks exhibiting a signal-to-noise ratio of 3 or
greater. We found that CSF prepared under denaturing
conditions without reduction performed best on all Pro-
teinChip arrays processed with either SPA or CHCA as the
matrix. With respect to the selection of binding buffer for
protein retention, buffer in the absence of Triton X-100
performed better on CM10 and Q10 arrays. For IMAC30
and H50 slightly higher peak numbers were obtained by
surface activation with copper, and using 10% AcN/0.1%
Venn diagram representing the overlap of peaks between ProteinChip array types Figure 4
Venn diagram representing the overlap of peaks between ProteinChip array types. CSF prepared in denaturing 
buffer was processed on CM10, Q10, H50 and IMAC30 ProteinChip arrays using (a) SPA, and (b) CHCA. Peaks with a signal-
to-noise ratio of 3 or greater, between the m/z range of 25–20 kD, were considered. When assigning peak clusters across 
spectra, two peaks on different surfaces were assumed to be the same protein if both their respective m/z were within 0.3%.
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TFA as binding buffer, respectively. However, the type of
matrix rather than the binding condition used on each
chip surface appears to dictate the overall protein profile
from each chip type. ProteinChip arrays prepared with
SPA consistently showed better peak sharpness and higher
peak number across all surfaces. The reliability of the
approach was emphasized with the low CVs which com-
pare favorably to the CVs reported for other protein pro-
filing approaches [34]. It's very likely that a major
contributor to this was the adaptation of the entire proc-
ess of ProteinChip preparation to a robotics system. Nev-
ertheless, we observed systematic variability across plates
processed at different times. Therefore, to ensure that sys-
tematic bias is minimized, sample randomization proce-
dures using technical replicates must be properly
addressed when large studies are conducted
Assessment of inter-chip variability Figure 5
Assessment of inter-chip variability. Spectra were obtained from a CSF sample of equal volume loaded across twelve 
chips used for one bioprocessor plate, and CVs calculated on normalized peak intensities. Four peaks, representing various 
intensities, are indicated along with their calculated CVs across the 12 chips.
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The surface-based enrichment approach using Protein-
Chips is a rapid and straightforward tool for screening
peptides and small proteins below 20 kDa from small
sample volumes. However, the major shortcomings of
this approach are peak identities and limited proteome
coverage. In this study, only a small subset of species, out
of potentially 100s' if not 1000s' of circulating molecules
in CSF, is actually monitored as peaks when the starting
material is unfractionated. Moreover, due to the high level
of overlap in profiles between the tested array types, we
observed that the combination of CM10 and IMAC30 was
sufficient enough to represent between 80–90% of all
assigned peaks on the tested arrays. Preferably, we would
have wanted a much lower overlap in profiles between the
array types so as to increase proteome coverage.
CSF contains a tremendous array of molecules, spanning
a concentration range of 10 orders of magnitude between
Assessment of systematic variability across bioprocessor plates using principle component analysis Figure 6
Assessment of systematic variability across bioprocessor plates using principle component analysis. Variability 
was evaluated across three bioprocessor plates processed 4 and 24 hours apart. Spectra were obtained from pooled CSF sam-
ple randomly placed on a single spot across each of twelve different CM10 chips on one bioprocessor plate. The same was 
repeated for the other plates 4 and 24 hr later. Following baseline subtraction, normalization and spectra alignment, 45 peaks 
which appeared in all spectra were used for PCA analysis. The PCA results were color coded for the three bioprocessor 
plates: blue, 0 hr; red, 4 hr; black, 24 h.
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the highest and lowest abundance proteins, of which only
a handful (e.g. albumin) constitute up to 90% of the total
protein concentration. Consequently, it is likely that the
low abundance molecules of diagnostic potential will be
competed out by high abundance non-informative mole-
cules for binding on the solid-phase. Indeed, most differ-
ences identified by this approach in body fluids have
shown bias towards the high abundant molecules
(present in the µg/mL to mg/mL concentration range)
implying that the ProteinChip SELDI-TOF technology is
probably not adequate for 'deep' proteome analysis [19].
Initial prefractionation of CSF by LC based methods, in
combination with immunodepletion of abundant pro-
teins, are thus likely obligatory steps for exploiting low-
abundant molecules of diagnostic potential [35,36]. Con-
currently, a balance must be found between analysis
depth, speed, throughput, and sample requirements.
Further developments in analytical strategies for selective
protein absorption on solid support coupled to high mass
accuracy and high resolution MS technology is necessary
before this approach can be used as a more comprehen-
sive proteomic profiling tool in an automated and high
throughput fashion. A promising area of development is
in the utilization of combinatorial ligands for mining the
proteome [38,39]. Libraries of potential millions of dis-
crete amino acid ligands synthesized on solid-phase beads
have been created, in which theoretically, there is a ligand
for every protein, antibody, and peptide present in the
starting material. It is envisaged that these beads impreg-
nated with complex proteomes could capture equal quan-
tities of each and all the peptides and proteins present in
CSF, thus reducing the concentration difference. This
could make proteomic approaches using ProteinChips
more adapted to 'deep' proteome analysis and biomarker
discovery. Another interesting approach was adopted by
both Mehta [39] and Zhou [40] to profile the proportion
of low molecular weight species bound to specific circulat-
ing carrier proteins. It was found that by selectively target-
ing high abundant proteins in serum for depletion, many
other peptides and small proteins associated with these
abundant proteins are concomitantly removed. By this
targeted selection, the concentrations of associated pep-
tides and small proteins are enriched to levels of detec-
tion. Indeed, some of the species identified represented
clinically relevant biomarkers, including prostate-specific
antigen which in healthy males is present at a concentra-
tion of 1 ng/mL. Examination of the low molecular weight
species bound to specific carrier proteins may, therefore,
allow for the detection and mining of diagnostic informa-
tion.
In spite of the current technical shortcomings of the Pro-
teinChip SELDI-TOF technology, one could envisage the
potential utilization of surface-based enrichment
approaches in combination with MS as a strictly high
throughput screening tool to drive decisions on sample
selection prior to more in-depth discovery of diagnostic
markers. For instance, the ProteinChip SELDI-TOF tech-
nology could be used as an upfront quality control step
for screening large sample numbers obtained from multi-
ple clinical centres. Multivariate analysis of the data sets
would help reveal potential sample outliers as a result of
either sample handling or intrinsic patient variability.
This would aid in the selection of a smaller sample subset
for more in-depth comparative analysis using alternative
proteomic platforms such as multidimensional LC-MS
based strategies.
Conclusion
In conclusion, we have shown that the ProteinChip
SELDI-TOF technology can provide a fast, robust, straight-
forward and reproducible profiling platform for measur-
ing peaks in the low molecular mass range of the CSF
proteome. We are currently examining the robustness of
the profile across patient sample sets from healthy, mild
cognitive impaired, AD, and other dementias in order to
address the feasibility of the current platform in combina-
tion with decision algorithms to detect biomarker panels
associated with the different pathological conditions, and
as a screening tool for sample selection prior to more in-
depth analysis.
Materials and methods
Cerebrospinal fluid samples
Normal CSF samples obtained from consenting patients
were provided by PrecisionMed Inc. (San Diego, CA). CSF
samples were obtained by lumbar puncture as part of a
routine clinical procedure. The samples were collected in
polypropylene tubes and gently mixed to avoid gradient
effects. The samples were centrifuged at 2000 × g for 10
min to remove cells and other insoluble material. Super-
natants were frozen in aliquots and stored at -80°C until
analysis.
Sample preparation
A standard pooled Human CSF sample was used to evalu-
ate the different conditions of retention on the all Protein-
Chip arrays. CSF samples were prepared on four different
ProteinChip array surfaces: cation-exchange (CM10),
strong anion-exchange (Q10); metal-binding (IMAC30)
and reverse phase (H50). All ProteinChip Arrays were
processed on the same day following the procedures rec-
ommended by the manufacturer. Binding buffers used for
the different arrays were 100 mM ammonium acetate pH
4.0 (with or without 0.1% Triton X-100) for CM10; 100
mM Tris-HCl pH 9.0 (with or without 0.1% Triton X-100)
for Q10; 100 mM Na phosphate, 500 mM NaCl pH 7.0
(activated with either 100 mM copper sulphate or 100
mM nickel sulphate hexahydrate) for IMAC30., 10% ace-Proteome Science 2006, 4:7 http://www.proteomesci.com/content/4/1/7
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tonitrile (AcN), 0.1% trifluoroacetic acid (TFA) or phos-
phate buffered saline (PBS) for H50.
Preliminary experiments were first performed on Protein-
Chip arrays spotted with different CSF sample volumes
prepared in different ratios of sample to binding buffer.
Based on the overall number of detected peaks and their
associated intensities we determined 5 µL of CSF diluted
1:4 in the appropriate binding buffer to be the optimal
amount for loading onto the ProteinChip arrays (data not
shown). Subsequent experiments reported in this paper
were performed using this CSF volume. In brief, 5 µL of
CSF was diluted 1:1 in sample buffer preparations repre-
senting the following conditions: native (dH2O), dena-
tured (9.5 M urea, 2% CHAPS, 50 mM Tris-HCl, pH 9.0)
and denatured/reduced (9.5 M urea, 2% CHAPS, 50 mM
Tris-HCl, 10 mM dithiothreitol, pH 9.0). Following 20
min incubation at 4°C, the CSF samples were then added
to separate spots on the array surface using a Biomek lab-
oratory station (Beckman-Coulter, CA) modified to make
use of a ProteinChip array bioprocessor (Ciphergen Bio-
systems Inc.). The samples on the arrays were diluted 1:4
in the appropriate ProteinChip array binding buffer. The
bioprocessor was then centrifuged for 10 s at 1000 rpm,
using an Eppendorf Centrifuge 5804 system, to remove
any air bubbles. The arrays were incubated for 1 h at room
temperature with gentle shaking. The ProteinChip arrays
were washed twice with 50 µL binding buffer for 5 min-
utes with gentle shaking, followed by two washes with
150 µL distilled water for 1 minute to remove buffer salts.
The bioprocessor was subsequently removed and the Pro-
teinChip arrays air-dried at 23°C for 15 minutes. Once
dry, two 1 µL aliquots of a 50% saturated sinapinic acid
(SPA; Ciphergen Biosystems Inc.) solution prepared in
50% acetonitrile and 0.5% TFA was added to each spot of
the ProteinChip array. The arrays were allowed to air-dry
before SELDI analysis. The same was repeated for Protein-
Chip arrays prepared with 50% saturated α-Cyano-4-
hydroxycinnamic acid (CHCA; Ciphergen Biosystems
Inc.) solution prepared in 50% acetonitrile and 0.5% TFA.
Each condition was analysed in triplicate. For storage, the
spotted arrays were kept in the dark at room temperature.
Data acquisition and spectral processing
ProteinChip arrays were placed in the ProteinChip reader
Series 4000 mass spectrometer (Ciphergen Biosystems
Inc.) and mass spectra was acquired using settings opti-
mized for the m/z range of 2.5–20 kDa. For each spot
around 175 shots were collected in positive ionization
mode using a laser intensity set at 1,500 nJ. For SPA prep-
arations a deflector setting of 1000 Da, and an ion focus
mass of 9000 Da was used, whereas for CHCA prepara-
tions a deflector setting of 500 Da, and an ion focus mass
of 3500 Da was used. The spectra were externally cali-
brated using the "All-In-One" peptide mass standard
(Ciphergen Biosystems Inc.). The standards, ranging from
1–7 kDa, were prepared on NP20 ProteinChip arrays
according to the manufactures recommendation. The Pro-
teinChip reader was calibrated daily and we typically
achieved mass accuracies within 150 ppm.
Spectra were analysed using Ciphergen Express software
Version 3.0.5 (Ciphergen Biosystems Inc.). The baseline
was subtracted (baseline smooth width of 25) and the
spectral intensities were normalized by total ion current
(TIC) to an external normalization coefficient of 0.2
between the mass range of 2.5 to 20 kDa. Automatic peak
detection was performed using the following settings:
noise calculation between the mass range of 2.5 to 20
kDa, 3 times the signal-to-noise ratio and 2 times the val-
ley depth for the first pass, and 2 times the signal-to-noise
ratio and 2 times the valley depth for the second pass. In
addition to the automatic assignment of peaks, manual
inspection of the spectra was conducted as a quality con-
trol step to ensure that all peaks were correctly labelled.
When assigning peak clusters across spectra, two peaks on
different surfaces were assumed to be the same protein if
both their respective m/z  were within 0.3%. Principle
component analysis was performed using the SIMCA-P
statistical package (Umetrics AB, Sweden), and was used
to reveal major variance structure and clustering.
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